---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-066825"
form_type: "8-K"
ticker: "SPRO"
cik: "0001701108"
company_name: "Spero Therapeutics, Inc."
filed_at: "2024-03-13T23:59:59+00:00"
generated_at: "2026-06-04T22:23:55.635441+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Spero Therapeutics reports Q4 2023 net income of $51.2M; SPR720 topline data expected 2H 2024

## Summary
- Q4 2023 net income of $51.2M ($0.96 diluted EPS) vs $26.8M in Q4 2022; full-year net income of $22.8M ($0.43 diluted EPS).
- Total revenue $73.5M in Q4 2023, up from $47.4M in Q4 2022, driven by $71.8M in GSK/Pfizer collaboration revenue.
- Cash and cash equivalents $76.3M at Dec 31, 2023; received $23.8M first tranche of $95M GSK milestone, expects cash runway into late 2025.
- SPR720 Phase 2a proof-of-concept topline data in NTM-PD expected in second half of 2024; Phase 3 PIVOT-PO trial for tebipenem HBr enrolling.
- Sath Shukla transitioned to President & CEO in August 2023; Esther Rajavelu appointed CFO/CBO in November 2023.

## SEC filing metadata
- accession: 0001193125-24-066825
- form_type: 8-K
- ticker: SPRO
- cik: 0001701108
- company_name: Spero Therapeutics, Inc.
- filed_at: 2024-03-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701108/000119312524066825/0001193125-24-066825-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701108/000119312524066825/d809069d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-066825
- JSON: https://secwatch.observer/filing/0001193125-24-066825.json
- Plain text: https://secwatch.observer/filing/0001193125-24-066825.txt

## Key facts
- Earnings Releases
  Spero Therapeutics, Inc. reported fourth quarter and full year ended December 31, 2023 results: net income Spero reported net income of $51.2 million for the fourth quarter and an overall net income of $22.8 million, for the ye, EPS $0.96 and $0.43.
  - Period: fourth quarter and full year ended December 31, 2023
  - Net income: Spero reported net income of $51.2 million for the fourth quarter and an overall net income of $22.8 million, for the ye
  - EPS: $0.96 and $0.43
  - Result: reported results
  source text: Spero reported net income of $51.2 million for the fourth quarter and an overall net income of $22.8 million, for the year ended December 31, 2023, or a diluted net income per share of common stock of $0.96 and $0.43, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1701108/000119312524066825/0001193125-24-066825-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.